Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419442 | 0.84 | LMNA (0.53) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL535788 | 0.82 | CES2 (0.51) | CES2CES1CHRM1LMNAALDH1A1 | |
| SCHEMBL535789 | 0.82 | CES2 (0.51) | CES2CES1CHRM1LMNAALDH1A1 | |
| SCHEMBL2418494 | 0.82 | TSHR (0.51) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL2417875 | 0.81 | TSHR (0.53) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL19086403 | 0.81 | CES2 (0.48) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL10680751 | 0.80 | CES2 (0.47) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL26785147 | 0.80 | CES2 (0.47) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL821932 | 0.79 | LMNA (0.52) | CES2CES1CHRM1CHRM3CHRM2 | |
| SCHEMBL13846306 | 0.79 | CES2 (0.55) | CES2CES1CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190131-B1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | UNIV KYOTO (JP) | 2020-07-29 | — | — | EP | disclosed |
| CN-106604938-B | Living radical polymerization initiator, method for producing polymer, and polymer | 国立大学法人京都大学 | 2020-03-31 | — | — | CN | disclosed |
| US-10414848-B2 | Living radical polymerization initiator, method for producing polymer, and polymer | KYOTO UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
| US-20170306073-A1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | KYOTO UNIVERSITY (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3190131-A1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | Kyoto University (JP) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414848-B2 | Living radical polymerization initiator, method for producing polymer, and polymer | CCNY, MTR, PARN | CES2 255/4885CES1 1362/4885CHRM1 558/4885 |
| US-20170306073-A1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | CCNY, MTR, PARN | CES2 255/4885CES1 1362/4885CHRM1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.